Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$144.13 USD
-1.50 (-1.03%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $144.02 -0.11 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Neurocrine Biosciences (NBIX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$167.25 | $219.00 | $100.00 | 14.85% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Neurocrine Biosciences comes to $167.25. The forecasts range from a low of $100.00 to a high of $219.00. The average price target represents an increase of 14.85% from the last closing price of $145.63.
Analyst Price Targets (24)
Broker Rating
Neurocrine Biosciences currently has an average brokerage recommendation (ABR) of 1.46 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.46 a month ago based on 26 recommendations.
Of the 26 recommendations deriving the current ABR, 20 are Strong Buy, representing 76.92% of all recommendations. A month ago, Strong Buy represented 76.92%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NBIX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 20 | 20 | 20 | 20 | 20 |
Buy | 0 | 0 | 0 | 0 | 1 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.46 | 1.46 | 1.46 | 1.46 | 1.48 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/1/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Piper Sandler | David Amsellem | Hold | Hold |
8/1/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
7/25/2024 | Needham & Company | Ami Fadia | Hold | Hold |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
6/21/2024 | Mizuho SecuritiesUSA | Uy D Ear | Hold | Hold |
5/16/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
5/2/2024 | BMO Capital Markets | Evan Seigerman | Hold | Hold |
5/2/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
5/1/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
4/24/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Strong Buy |
4/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/10/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
3/14/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1/25/2024 | Goldman Sachs | Chris Shibutani | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.46 |
ABR (Last week) | 1.46 |
# of Recs in ABR | 26 |
Average Target Price | $167.25 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 104 of 253 |
Current Quarter EPS Est: | 1.45 |